Apeiron Therapeutics intends to develop breakthrough investigational medicines by harnessing the power of artificial intelligence which drastically increases efficiency throughout the drug discovery process, from target selection, hit identification, lead optimization to pre-clinical studies and clinical trials. GT Apeiron is strategically based in Shanghai and in the San Francisco Bay Area, with significant collaborations in the UK enabling us to tap into technologies and talent from all three continents.